See the published version of this article at BMC Neurology.
This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Learn more about In Review
Research article
Inflammation biomarker discovery in Parkinson's disease and atypical parkinsonisms
Marcel Verbeek
Radboudumc
Corresponding Author
ORCiD: https://orcid.org/0000-0003-4635-7876
License:
This work is licensed under a CC BY 4.0 License. Read Full License
View the published version at BMC Neurology.
Background: Parkinson’s disease (PD) and atypical parkinsonisms (APD) have overlapping symptoms challenging an early diagnosis. Diagnostic accuracy is important because PD and APD have different prognosis and response to treatment. We aimed to identify diagnostic inflammatory biomarkers of PD and APD in cerebrospinal fluid (CSF) using the multiplex proximity extension assay (PEA) technology and to study possible correlations of biomarkers with disease progression.
Methods: CSF from a longitudinal cohort study consisting of PD and APD patients (PD, n = 44; multiple system atrophy (MSA), n = 14; vascular parkinsonism (VaP), n = 9; and PD with VaP, n = 7) and controls (n = 25) were analyzed.
Results: Concentrations of CCL28 were elevated in PD compared to controls (p = 0.0001). Five other biomarkers differentiated both MSA and PD from controls (p < 0.05) and 10 biomarkers differentiated MSA from controls, of which two proteins, i.e. beta nerve growth factor (β-NGF) and Delta and Notch like epidermal growth factor-related receptor (DNER), were also present at lower levels in MSA compared to PD (both p = 0.032). Two biomarkers (MCP-1 and MMP-10) positively correlated with PD progression (rho > 0.650; p < 0.01).
Conclusions: PEA technique identified potential new CSF biomarkers to help to predict the prognosis of PD. Also, we identified new candidate biomarkers to distinguish MSA from PD.
Keywords
Parkinson’s disease, Multiple System Atrophy, biomarkers, inflammation
Figure 1
Figure 2
This is a list of supplementary files associated with this preprint. Click to download.
1 comment flagged for moderation
If you posted a comment and think it was mistakenly removed, please contact customer support at [email protected].
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
Peer Review Timeline
CURRENT STATUS: Published
Version 4
Posted 13 Jan, 2020
Published
On 17 Jan, 2020
No community comments so far
Editorial decision: Accept
On 09 Jan, 2020
Editor assigned
On 09 Jan, 2020
Submission checks complete
On 08 Jan, 2020
Editor invited
On 08 Jan, 2020
No comments provided
Editorial decision: Minor revision
On 26 Dec, 2019
Review #2 received
Received 11 Dec, 2019
Reviewers invited
Invitations sent on 11 Dec, 2019
Reviewer #1 agreed
On 11 Dec, 2019
Reviewer #2 agreed
On 11 Dec, 2019
Review #1 received
Received 11 Dec, 2019
Editor assigned
On 01 Dec, 2019
Submission checks complete
On 30 Nov, 2019
Editor invited
On 30 Nov, 2019
No comments provided
Editorial decision: Minor revision
On 27 Nov, 2019
Review #1 received
Received 22 Nov, 2019
Review #2 received
Received 22 Nov, 2019
Editor assigned
On 15 Nov, 2019
Reviewers invited
Invitations sent on 15 Nov, 2019
Reviewer #1 agreed
On 15 Nov, 2019
Reviewer #2 agreed
On 15 Nov, 2019
Submission checks complete
On 14 Nov, 2019
Editor invited
On 14 Nov, 2019
No comments provided
Review #2 received
Received 09 Oct, 2019
Editorial decision: Major revision
On 09 Oct, 2019
Reviewer #2 agreed
On 28 Sep, 2019
Review #1 received
Received 19 Sep, 2019
Reviewer #1 agreed
On 16 Sep, 2019
Reviewers invited
Invitations sent on 13 Sep, 2019
Editor assigned
On 12 Sep, 2019
Submission checks complete
On 11 Sep, 2019
Editor invited
On 11 Sep, 2019
First submitted
On 07 Aug, 2019
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Subject Areas
Neurosurgery
Learn more about our company.
This preprint is under consideration at BMC Neurology. A preprint is a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Learn more about In Review
Research article
Inflammation biomarker discovery in Parkinson's disease and atypical parkinsonisms
Marcel Verbeek
Radboudumc
Corresponding Author
ORCiD: https://orcid.org/0000-0003-4635-7876
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
Peer Review Timeline
CURRENT STATUS: Published
Version 4
Posted 13 Jan, 2020
Published
On 17 Jan, 2020
No community comments so far
Editorial decision: Accept
On 09 Jan, 2020
Editor assigned
On 09 Jan, 2020
Submission checks complete
On 08 Jan, 2020
Editor invited
On 08 Jan, 2020
No comments provided
Editorial decision: Minor revision
On 26 Dec, 2019
Review #2 received
Received 11 Dec, 2019
Reviewers invited
Invitations sent on 11 Dec, 2019
Reviewer #1 agreed
On 11 Dec, 2019
Reviewer #2 agreed
On 11 Dec, 2019
Review #1 received
Received 11 Dec, 2019
Editor assigned
On 01 Dec, 2019
Submission checks complete
On 30 Nov, 2019
Editor invited
On 30 Nov, 2019
No comments provided
Editorial decision: Minor revision
On 27 Nov, 2019
Review #1 received
Received 22 Nov, 2019
Review #2 received
Received 22 Nov, 2019
Editor assigned
On 15 Nov, 2019
Reviewers invited
Invitations sent on 15 Nov, 2019
Reviewer #1 agreed
On 15 Nov, 2019
Reviewer #2 agreed
On 15 Nov, 2019
Submission checks complete
On 14 Nov, 2019
Editor invited
On 14 Nov, 2019
No comments provided
Review #2 received
Received 09 Oct, 2019
Editorial decision: Major revision
On 09 Oct, 2019
Reviewer #2 agreed
On 28 Sep, 2019
Review #1 received
Received 19 Sep, 2019
Reviewer #1 agreed
On 16 Sep, 2019
Reviewers invited
Invitations sent on 13 Sep, 2019
Editor assigned
On 12 Sep, 2019
Submission checks complete
On 11 Sep, 2019
Editor invited
On 11 Sep, 2019
First submitted
On 07 Aug, 2019
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Subject Areas
Neurosurgery
License:
This work is licensed under a CC BY 4.0 License. Read Full License
View the published version at BMC Neurology.
Background: Parkinson’s disease (PD) and atypical parkinsonisms (APD) have overlapping symptoms challenging an early diagnosis. Diagnostic accuracy is important because PD and APD have different prognosis and response to treatment. We aimed to identify diagnostic inflammatory biomarkers of PD and APD in cerebrospinal fluid (CSF) using the multiplex proximity extension assay (PEA) technology and to study possible correlations of biomarkers with disease progression.
Methods: CSF from a longitudinal cohort study consisting of PD and APD patients (PD, n = 44; multiple system atrophy (MSA), n = 14; vascular parkinsonism (VaP), n = 9; and PD with VaP, n = 7) and controls (n = 25) were analyzed.
Results: Concentrations of CCL28 were elevated in PD compared to controls (p = 0.0001). Five other biomarkers differentiated both MSA and PD from controls (p < 0.05) and 10 biomarkers differentiated MSA from controls, of which two proteins, i.e. beta nerve growth factor (β-NGF) and Delta and Notch like epidermal growth factor-related receptor (DNER), were also present at lower levels in MSA compared to PD (both p = 0.032). Two biomarkers (MCP-1 and MMP-10) positively correlated with PD progression (rho > 0.650; p < 0.01).
Conclusions: PEA technique identified potential new CSF biomarkers to help to predict the prognosis of PD. Also, we identified new candidate biomarkers to distinguish MSA from PD.
Figure 1
Figure 2